Letter: Cancer treatment
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir: Professor John Smyth is quite right to call for more cancer patients to be referred to major centres ('Cancer expert attacks 'cowboy' doctors', 1 December). Not only is there increasing evidence that patients treated at these hospitals have a better chance of survival, but in addition they are much more likely to be treated according to strict protocols, often participating in the clinical trials that are so important if we are to establish better treatments. Only this morning an important study from the Royal Marsden Hospital, one of our best treatment centres, has suggested that there might be an improved outcome in breast cancer patients treated with a novel type of infusional chemotherapy. Studies like this rely on a steady flow of patients in order to achieve proper confirmation of exciting preliminary results.
Large cancer treatment centres are accused of being more expensive on a 'per patient' basis, but the truth is that the quality of treatment tends to be better, and the patient far more likely to make a real contribution to future knowledge via protocol-guided clinical trials.
We are all potential patients, yet despite the generally poor results with cancer, only 10 per cent or fewer are entered on clinical studies. 'Patient power' should be encouraged; in my view the only way forward is through proper education of patients so they understand their right to be treated in the well equipped centre of their choice. After all, was this not the essential philosophy behind the newly commercialised health service?
Yours sincerely,
JEFFREY TOBIAS
Clinical Director
Cancer Services
UCH/Middlesex Hospitals
London, W1
2 December
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments